FDA Forms Advisory Committee to Review Low-Dose Atropine for Pediatric Myopia

The U.S. Food and Drug Administration (FDA) is convening an advisory committee meeting to review Sydnexis, Inc.'s SYD-101, an investigational low-dose atropine formulation for pediatric progressive myopia (PPM). This development follows the federal agency's rejection of the eye drop's new drug application nearly nine months prior.